RNS Number : 2620R
05 July 2022
5 July 2022 07:00 BST
AstraZeneca to acquire TeneoTwo and its clinical-stage
T-cell engager, strengthening haematological cancer pipeline
TNB-486 will be evaluated in multiple types of lymphoma
AstraZeneca today announced an agreement to acquire TeneoTwo,
Inc. (TeneoTwo) (i) , including its Phase I clinical-stage CD19/CD3
T-cell engager, TNB-486 , currently under evaluation in relapsed
and refractory B-cell non-Hodgkin lymphoma(1) .
The acquisition of TNB-486 aims to accelerate the development of
this potential new medicine for B-cell haematologic malignancies,
including diffuse large B-cell lymphoma and follicular lymphoma.
Building on the success of Calquence (acalabrutinib), TNB-486
further diversifies AstraZeneca's haematology pipeline that spans
multiple therapeutic modalities and mechanisms to address a broad
spectrum of blood cancers .
TNB-486 belongs to a class of therapeutic antibodies known as
T-cell engagers, which are emerging as a promising therapeutic
approach in haematologic malignancies and solid tumours. T-cell
engagers are bispecific molecules that are engineered to redirect
the immune system's T-cells to recognise and kill cancer cells. By
binding to both CD19, an antigen expressed on B-cells, and to the
CD3 receptor on T-cells, TNB-486 activates and recruits T-cells to
CD19-expressing tumours where they can elicit an immune
Anas Younes, Senior Vice President Haematology R&D,
AstraZeneca said: "By redirecting the body's natural immune
response to target B-cell malignancies, TNB-486 alone or in
combination with CD20-targeted therapy could potentially deepen
clinical responses and improve patient outcomes. We believe this
innovative molecule, which was designed to optimise the therapeutic
window of T-cell activation, will enable us to explore novel
combinations that have the potential to become new standards of
care in this setting."
AstraZeneca will acquire all outstanding equity of TeneoTwo in
exchange for an upfront payment of $100m on deal closing.
Under the terms of the agreement, AstraZeneca will make
additional contingent R&D-related milestone payments of up to
$805m and additional contingent commercial-related milestone
payments of up to $360m to TeneoTwo's equity holders.
Overall, the transaction will be accounted for as an intangible
asset acquisition, recognised initially at the present value of
non-contingent consideration, with future milestones capitalised
into the intangible asset as they are recognised.
The transaction is expected to close in the third quarter of
2022, subject to customary closing conditions and regulatory
clearances. The transaction does not impact AstraZeneca's financial
guidance for 2022.
(i) TeneoTwo, Inc., is a majority owned subsidiary company of
TBio, LLC, a limited liability company formed in Delaware, US
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the
ambition to provide cures for cancer in every form, following the
science to understand cancer and all its complexities to discover,
develop and deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers.
It is through persistent innovation that AstraZeneca has built one
of the most diverse portfolios and pipelines in the industry, with
the potential to catalyse changes in the practice of medicine and
transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day,
eliminate cancer as a cause of death.
AstraZeneca in haematology
AstraZeneca is pushing the boundaries of science to redefine
care in haematology. We have expanded our commitment to patients
with haematologic conditions, not only in oncology but also in rare
diseases with the acquisition of Alexion, allowing us to reach more
patients with high unmet needs. By applying our deep understanding
of blood cancers, leveraging our strength in solid tumour oncology
and delivering on Alexion's pioneering legacy in complement science
to provide transformative medicines for rare diseases, we are
pursuing the end-to-end development of novel therapies designed to
target underlying drivers of disease.
By targeting haematological conditions with high unmet medical
needs, we aim to deliver innovative medicines and approaches to
improve patient outcomes. Our goal is to help transform the lives
of patients living with malignant, rare and other related
haematologic diseases, shaped by insights from patients, caregivers
and physicians to have the most meaningful impact.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @ AstraZeneca .
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
1. Clinicaltrials.gov. A Study of TNB-486 in Subjects With
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Available at
https://clinicaltrials.gov/ct2/show/NCT04594642 . Accessed 27 June
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact firstname.lastname@example.org or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
July 05, 2022 02:00 ET (06:00 GMT)
Gráfica de Acción Histórica
De Jul 2022 a Ago 2022
Gráfica de Acción Histórica
De Ago 2021 a Ago 2022